FCM scores of controls and LGw/oRS patients
. | First cohort . | . | Second cohort . | . | Both cohorts . | . | |||
|---|---|---|---|---|---|---|---|---|---|
. | Controls, no. . | LGw/oRS patients, no. . | Controls, no. . | LGw/oRS patients, no. . | Controls, no. . | LGw/oRS patients, no. . | |||
| Total | 50 | 12 | 40 | 15 | 90 | 27 | |||
| Score | |||||||||
| 0 | 40 | 1 | 31 | 2 | 71 | 3 | |||
| 1 | 4 | 1 | 9 | 1 | 13 | 2 | |||
| 2 | 6 | 3 | 0 | 3 | 6 | 6 | |||
| 3 | 0 | 2 | 0 | 4 | 0 | 6 | |||
| 4 | 0 | 1 | 0 | 3 | 0 | 4 | |||
| 5 | 0 | 3 | 0 | 1 | 0 | 4 | |||
| 6 | 0 | 1 | 0 | 0 | 0 | 1 | |||
| 7 | 0 | 0 | 0 | 1 | 0 | 1 | |||
| 3 or higher | 0 | 7 | 0 | 9 | 0 | 16 | |||
. | First cohort . | . | Second cohort . | . | Both cohorts . | . | |||
|---|---|---|---|---|---|---|---|---|---|
. | Controls, no. . | LGw/oRS patients, no. . | Controls, no. . | LGw/oRS patients, no. . | Controls, no. . | LGw/oRS patients, no. . | |||
| Total | 50 | 12 | 40 | 15 | 90 | 27 | |||
| Score | |||||||||
| 0 | 40 | 1 | 31 | 2 | 71 | 3 | |||
| 1 | 4 | 1 | 9 | 1 | 13 | 2 | |||
| 2 | 6 | 3 | 0 | 3 | 6 | 6 | |||
| 3 | 0 | 2 | 0 | 4 | 0 | 6 | |||
| 4 | 0 | 1 | 0 | 3 | 0 | 4 | |||
| 5 | 0 | 3 | 0 | 1 | 0 | 4 | |||
| 6 | 0 | 1 | 0 | 0 | 0 | 1 | |||
| 7 | 0 | 0 | 0 | 1 | 0 | 1 | |||
| 3 or higher | 0 | 7 | 0 | 9 | 0 | 16 | |||
* One point was given for each FCM parameter selected from Table 2 (ie, stage I hematogones, CD34+ myeloblasts, CD4, CD56, CD11b, CD13, CD15, CD33, CD117, and CD133) if the data on each parameter were outside the RR.